Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma

Medical Oncology

Volumn 32, Issue 4, 2015, Pages

  Yang, Linlin ^a   Hu, Baoying ^b   Zhang, Yixin ^a   Qiang, Songlin ^a   Cai, Jin ^a   Huang, Wei ^b   Gong, Chen ^b   Zhang, Tingting ^b   Zhang, ShuSen ^b   Xu, Pan ^b   Wu, Xuming ^a   Liu, Jibin ^a  

^a Nantong Tumor Hospital   (China)

^b NANTONG MEDICAL COLLEGE   (China)

Author keywords

Hepatocellular carcinoma; KPN 1; NF B P65; Proliferation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KARYOPHERIN BETA; KARYOPHERIN BETA1; UNCLASSIFIED DRUG; KPNB1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; AGED; CANCER TISSUE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HEPG2 CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LIVER; LIVER TUMOR; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; YOUNG ADULT;

ADULT; AGED; BETA KARYOPHERINS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84925353139     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0559-1     Document Type: Letter

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Tsochatzis EA, Meyer T, Burroughs AK. Hepatocellular carcinoma. N Engl J Med. 2012;366(1):92.
3. Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013;57(2):610–24.
4. Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 2014;111(7):101–6.
5. Moudgil V, Redhu D, Dhanda S, Singh J. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol. 2013;32(2):165–75.
6. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.
7. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 2003;3(6):573–88.
8. Zhao ZK, Dong P, Gu J, Chen L, Zhuang M, Lu WJ, et al. Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma. Tumor Biol. 2013;34(1):173–80.
9. Nakielny S, Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell. 1999;99(7):677–90.
10. Mosammaparast N, Pemberton LF. Karyopherins: from nuclear-transport mediators to nuclear-function regulators. Trends Cell Biol. 2004;14(10):547–56.
11. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol. 2001;11(6):703–15.
12. Kohler M, Speck C, Christiansen M, Bischoff FR, Prehn S, Haller H, et al. Evidence for distinct substrate specificities of importin alpha family members in nuclear protein import. Mol Cell Biol. 1999;19(11):7782–91.
13. Kau TR, Silver PA. Nuclear transport as a target for cell growth. Drug Discov Today. 2003;8(2):78–85.
14. van der Watt PJ, Stowell CL, Leaner VD. The nuclear import receptor Kpnbeta1 and its potential as an anticancer therapeutic target. Crit Rev Eukaryot Gene Expr. 2013;23(1):1–10.
15. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4(2):106–17.
16. Zhang P, Garnett J, Creighton CJ, Al Sannaa GA, Igram DR, Lazar A, et al. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis. J Pathol. 2014;232(3):308–18.
17. Angus L, van der Watt PJ, Leaner VD. Inhibition of the nuclear transporter, Kpnbeta1, results in prolonged mitotic arrest and activation of the intrinsic apoptotic pathway in cervical cancer cells. Carcinogenesis. 2014;35(5):1121–31.
18. Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, et al. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer. Clin Cancer Res. 2013;19(8):1994–2003.
19. Edick MJ, Cheng C, Yang W, Cheok M, Wilkinson MR, Pei D, et al. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosom Cancer. 2005;42(2):107–16.
20. Liang P, Zhang H, Wang G, Li S, Cong S, Luo Y, et al. KPNB1, XPO7 and IPO8 mediate the translocation of NF-kappaB/P65 into the nucleus. Traffic. 2013;14(11):1132–43.
21. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253(3):453–69.
22. Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Ther Adv Gastroenterol. 2010;3(1):55–66.
23. Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol. 2012;27(5):862–72.
24. Dhir M, Lyden ER, Smith LM, Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB. 2012;14(9):635–45.
25. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.
26. Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56(4):1371–9.
27. Zhu Y, Liu Y, Qian Y, Dai X, Yang L, Chen J, et al. Research on the efficacy of Celastrus Orbiculatus in suppressing TGF-beta1-induced epithelial-mesenchymal transition by inhibiting HSP27 and TNF-alpha-induced NF-kappaB/Snail signaling pathway in human gastric adenocarcinoma. BMC Complement Altern Med. 2014;14:433.
28. Tsao SM, Hsia TC, Yin MC. Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-kappaB pathways. Nutr Cancer. 2014;66(8):1331–41.
29. Gao X, Liu Y, Deeb D, Arbab AS, Gautam SC. Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-kappaB/mTOR signaling. J Exp Ther Oncol. 2014;10(4):275–83.
30. Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappaB drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014;60(5):1659–73.
31. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–83.
32. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.
33. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621–63.